Kolexia
Petit Thierry Oncologie médicale
Petit Thierry
Oncologie médicale
Centre Paul Strauss
Strasbourg, France
240 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Cancers du sein inflammatoires Tumeurs du sein triple-négatives Récidive tumorale locale Carcinomes Tumeur du sein de l'homme Tumeurs de l'ovaire Carcinome canalaire du sein

Collaborateurs

Voir plus
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France

Industries

Voir plus
A+A
36 collaboration(s)
Dernière en 2023
Novartis
29 collaboration(s)
Dernière en 2023
CanceroDigest
23 collaboration(s)
Dernière en 2023
Pfizer
19 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
TREAT ctDNA: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Essai Clinique (Menarini)   23 janvier 2024
Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer.
JNCI cancer spectrum   19 décembre 2023
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
European journal of cancer (Oxford, England : 1990)   10 novembre 2023
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   02 novembre 2023
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
JAMA network open   01 novembre 2023
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.
Cancers   11 octobre 2023